GleamWall
中文EN

MTVA MetaVia Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1638287 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY3.2%
TTM EPS YoY93.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-359.0%
ROA-129.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets74.8%
Debt / equity0.00x
Current ratio1.32x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.06x
Accruals ratio7.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$6.80M$21.55M
SG&A expense$6.91M$7.26M
Operating income-$13.71M-$28.81M
Pretax income-$12.97M-$27.59M
Income tax$0$0
Net income-$12.97M-$27.59M
EBITDA-$13.69M-$28.79M
EPS (basic)-7.35-39.13
EPS (diluted)-7.35-39.13
Weighted avg. shares (diluted)1.77M705,193
Banking
Net interest income$510,000$920,000
Balance sheet
Cash & equivalents$10.28M$16.02M
Current assets$10.88M$16.07M
PP&E, net$17,000$34,000
Total assets$11.12M$16.26M
Current liabilities$5.65M$8.27M
Total liabilities$5.79M$8.33M
Shareholders' equity$5.33M$7.93M
Shares outstanding2.31M785,194
Cash flow statement
Operating cash flow-$15.70M-$24.71M
Capital expenditure$2,000$8,000
Free cash flow-$15.70M-$24.72M
Investing cash flow-$2,000-$8,000
Financing cash flow$9.96M$18.30M
Depreciation & amortization$19,000$20,000
Stock-based compensation$411,000$538,000

Free plan shows the latest 2 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.